Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock

Sanofi has cut its last remaining link with Alnylam, 5 years after the two first began their collaboration and just weeks since the Boston biotech told investors that they were formally ending the partnership.